Literature DB >> 23619963

Dietary tryptophan manipulation reveals a central role for serotonin in the anabolic response of appendicular skeleton to physical activity in rats.

Valeria Sibilia1, Francesca Pagani, Elisa Dieci, Emanuela Mrak, Marcella Marchese, Guido Zarattini, Francesca Guidobono.   

Abstract

Several studies support a serotonin role in the physiological control of bone mass. However, whether serotonin (5-HT) is involved in bone loss due to reduced mechanical stress or unloading is unknown. We investigated the effects of reduced 5-HT tone, induced by tryptophan-free diet, in movement-restraint osteopenia induced by housing mature rats, acclimatised in single cages with a floor area of 1,500 cm(2), in smaller size single cages where their motor activity was reduced. Tryptophan-deficiency significantly worsened movement-restraint-induced bone loss in both femoral metaphysis and diaphysis (DXA analysis) but not at lumbar vertebrae and impaired the mechanical properties of the femur by significantly reducing both cortical thickness and strength strain index (pQCT analysis). Such effects resulted from an impairment of bone turnover with bone resorption exceeding bone formation. Tryptophan-supplemented diet reversed the worsening effects of tryptophan-deficiency on movement-restraint osteopenia. The improvements of both bone mass and strength were associated with an increase of serum osteocalcin and IGF-I, markers of osteoblast activity. In vitro studies in primary cultures of rat osteoblasts suggest that the anabolic action of 5-HT involves the activation of the Wnt/β-catenin pathway. Serotonin significantly increased the cytoplasmatic β-catenin protein levels by the inhibition of the enzyme glycogen synthase kinase-3β, that by phosphorylating β-catenin promotes its degradation. Our data support a role for 5-HT in the anabolic response of the appendicular skeleton to mechanical loading. We suggest that serotonin might stimulate canonical Wnt/β-catenin-dependent bone formation to occur.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23619963     DOI: 10.1007/s12020-013-9962-6

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.633


  40 in total

1.  Inhibition of the serotonin (5-hydroxytryptamine) transporter reduces bone accrual during growth.

Authors:  Stuart J Warden; Alexander G Robling; Megan S Sanders; Michael M Bliziotes; Charles H Turner
Journal:  Endocrinology       Date:  2004-11-11       Impact factor: 4.736

2.  Long-term serotonin administration leads to higher bone mineral density, affects bone architecture, and leads to higher femoral bone stiffness in rats.

Authors:  Björn I Gustafsson; Irene Westbroek; Jan H Waarsing; Helge Waldum; Erik Solligård; Anders Brunsvik; Sigbjørn Dimmen; Johannes P T M van Leeuwen; Harrie Weinans; Unni Syversen
Journal:  J Cell Biochem       Date:  2006-04-15       Impact factor: 4.429

3.  The Wnt co-receptor LRP5 is essential for skeletal mechanotransduction but not for the anabolic bone response to parathyroid hormone treatment.

Authors:  Kimihiko Sawakami; Alexander G Robling; Minrong Ai; Nathaniel D Pitner; Dawei Liu; Stuart J Warden; Jiliang Li; Peter Maye; David W Rowe; Randall L Duncan; Matthew L Warman; Charles H Turner
Journal:  J Biol Chem       Date:  2006-06-20       Impact factor: 5.157

Review 4.  Relationships between fat and bone.

Authors:  I R Reid
Journal:  Osteoporos Int       Date:  2007-10-27       Impact factor: 4.507

Review 5.  Mechanotransduction in osteoblast regulation and bone disease.

Authors:  Katerina K Papachroni; Demetrios N Karatzas; Kostas A Papavassiliou; Efthimia K Basdra; Athanasios G Papavassiliou
Journal:  Trends Mol Med       Date:  2009-04-08       Impact factor: 11.951

Review 6.  New understanding and treatments for osteoporosis.

Authors:  G Mazziotti; J Bilezikian; E Canalis; D Cocchi; A Giustina
Journal:  Endocrine       Date:  2012-02       Impact factor: 3.633

Review 7.  Regulation of bone mass by Wnt signaling.

Authors:  Venkatesh Krishnan; Henry U Bryant; Ormond A Macdougald
Journal:  J Clin Invest       Date:  2006-05       Impact factor: 14.808

8.  Neurotransmitter action in osteoblasts: expression of a functional system for serotonin receptor activation and reuptake.

Authors:  M M Bliziotes; A J Eshleman; X W Zhang; K M Wiren
Journal:  Bone       Date:  2001-11       Impact factor: 4.398

9.  Bone biomechanical properties in LRP5 mutant mice.

Authors:  M P Akhter; D J Wells; S J Short; D M Cullen; M L Johnson; G R Haynatzki; P Babij; K M Allen; P J Yaworsky; F Bex; R R Recker
Journal:  Bone       Date:  2004-07       Impact factor: 4.398

10.  Lrp5 functions in bone to regulate bone mass.

Authors:  Yajun Cui; Paul J Niziolek; Bryan T MacDonald; Cassandra R Zylstra; Natalia Alenina; Daniel R Robinson; Zhendong Zhong; Susann Matthes; Christina M Jacobsen; Ronald A Conlon; Robert Brommage; Qingyun Liu; Faika Mseeh; David R Powell; Qi M Yang; Brian Zambrowicz; Han Gerrits; Jan A Gossen; Xi He; Michael Bader; Bart O Williams; Matthew L Warman; Alexander G Robling
Journal:  Nat Med       Date:  2011-05-22       Impact factor: 53.440

View more
  3 in total

1.  Selective serotonin reuptake inhibitors and the risk of osseointegrated implant failure: a cohort study.

Authors:  X Wu; K Al-Abedalla; E Rastikerdar; S Abi Nader; N G Daniel; B Nicolau; F Tamimi
Journal:  J Dent Res       Date:  2014-09-03       Impact factor: 6.116

2.  Serum serotonin levels and bone in rheumatoid arthritis patients.

Authors:  Miguel Bernardes; Tiago Vieira; Raquel Lucas; Jorge Pereira; Lúcia Costa; Francisco Simões-Ventura; Maria João Martins
Journal:  Rheumatol Int       Date:  2017-10-09       Impact factor: 2.631

3.  A comparison of micro-CT and dental CT in assessing cortical bone morphology and trabecular bone microarchitecture.

Authors:  Jui-Ting Hsu; Ying-Ju Chen; Jung-Ting Ho; Heng-Li Huang; Shun-Ping Wang; Fu-Chou Cheng; Jay Wu; Ming-Tzu Tsai
Journal:  PLoS One       Date:  2014-09-16       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.